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Abstract Objective: Preclinical investigations have
established that methamphetamine (MA) produces long-
term changes in dopamine (DA) neurons in the striatum.
Human studies have suggested similar effects and
correlated motor and cognitive deficits. The present
study was designed to further our understanding of
changes in brain function in humans that might result
from chronic high dose use of MA after at least 3 months
of abstinence. Method: Brain function in abstinent users
was compared to controls using neuroimaging of mono-
amine transporters and cognitive assessment. Striatal levels
of DA transporter (DAT) and vesicular monoamine
transporter type-2 (VMAT2) were determined using [11C]
methylphenidate and [11C]dihydrotetrabenazine positron
emission tomography, respectively. Cognitive function was
evaluated using tests of motor function, memory, learning,
attention, and executive function. Results: Striatal DAT
was approximately 15% lower and VMAT2 was 10%
lower in MA abusers across striatal subregions. The MA
abusers performed within the normal range but performed
more poorly compared to controls on three of the 12 tasks.
Conclusions: Failure to find more substantial changes in
transporter levels and neurocognitive function may be
attributed to the length of time that MA users were
abstinent (ranging from 3 months to more than 10 years,
mean 3 years), although there were no correlations with
length of abstinence. Persistent VMAT2 reductions support
the animal literature indicating a toxic effect of MA on
nigrostriatal nerve terminals. However, the magnitude of
the MA effects on nigrostriatal projection integrity is
sufficiently small that it is questionable whether clinical
signs of DA deficiency are likely to develop.
Keywords Methamphetamine . Human . Neurocognitive
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Introduction
Laboratory investigations conducted over the past 25 years
in nonhumans have clearly established that administration
of amphetamines can produce long-term neurochemical
and structural changes in dopamine (DA) and serotonin
(5-HT) neurons in certain brain regions (Lew and Malberg
1997). Specifically, it was shown that high dose metham-
phetamine (MA) produces long-lasting decreases in the
brain levels of DA and serotonin; plasmalemmal reuptake
transporters for dopamine (DAT) and serotonin; and the
rate-limiting neurotransmitter synthesizing enzymes, tyro-
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sine hydroxylase, and tryptophan hydroxylase (Hotchkiss
and Gibb 1980; Ricaurte et al. 1982; Seiden et al. 1976;
Seiden and Ricaurte 1987; Wagner et al. 1980). Further,
there is morphological evidence of neurotoxicity on DA
nerve terminals (Lorez 1981). On the other hand, there is
histological evidence that indicates there is no degeneration
of the axon trunks or somata of the DA and 5-HT neurons,
which makes it likely that regeneration of the axon
terminals could take place (Ricaurte et al. 1982).
Human neuroimaging studies have also reported long-
term neurochemical differences when former high dose
MA abusers were compared to nondrug-abusing age- and
sex-matched controls. Ernst et al. (2000) using a magnetic
resonance (MR) scan, found decrease in concentrations of
N-acetylaspartate (NAA) in the basal ganglia and frontal
white matter of individuals in treatment for MA depen-
dence relative to matched controls. Nordahl et al. (2002)
reported decrease in concentrations of NAA in cerebral
cortical regions of the brain rich in DA innervation (e.g.,
anterior cingulate) in individuals who were abstinent for 4
to 13 weeks compared to age-matched controls. A study by
Thompson et al. (2004) in current MA users using high-
resolution (3 Tesla) structural MR imaging showed atrophy
of the cingulate, limbic, paralimbic cortices and hippo-
campus, and white matter hypertrophy. While the mech-
anism underlying these structural abnormalities cannot be
determined from these data with certainty, the investigators
suggested cell death as a possibility.
Positron emission tomography (PET) studies investigat-
ing the consequences of high dose amphetamine abuse in
humans have utilized ligands that bind to DAT. McCann et
al. (1998) studied individuals who had abused high doses
of MA for long periods of time but were abstinent for an
average of 3 years. Relative to controls, DAT binding in the
caudate and putamen were reduced 23 and 25%,
respectively. Volkow et al. (2001b) also demonstrated
significantly lower DAT binding in the caudate and
putamen, 28 and 21%, respectively, of MA abusers who
were abstinent from 2 weeks to 36 months (average of
6 months) relative to controls. These researchers (Volkow
et al. 2001a) conducted further evaluations on a subgroup
of five MA users from the previous study. These
individuals were abstinent on an average of 3 months in
the first study but were abstinent for at least nine more
months. Results of the second PET scan demonstrated
partial recovery in DAT binding with degree of recovery
related to length of abstinence. Sekine and colleagues
(Sekine et al. 2001, 2003) also demonstrated decreases in
DAT binding in the striatum and nucleus accumbens in MA
users abstinent for 7 days to 1.5 years (average 6 months)
compared to controls. The decreases were correlated with
duration of use and to some extent, with psychiatric
symptoms but not duration of abstinence. Unlike previous
studies, these MA users recruited from hospital centers in
Japan were not polydrug users except for nicotine and
alcohol.
The decrease in levels of DAT binding seen in these
studies could result from a decrease in the expression level
of the protein within DA terminals, a subcellular relocation
of the protein or DA neuron terminal degeneration. A
postmortem study of the striata of active MA abusers found
reductions in the concentrations of DA, tyrosine hydrox-
ylase, and DAT but not in levels of aromatic amino acid
decarboxylase (AADC), or VMAT2 (Wilson et al. 1996).
These investigators argued that because AADC and
VMAT2 concentrations are more stable indicators of the
structural integrity of nerve terminals than the DAT, this
evidence indicates that the DA nerve terminals are
biochemically altered by acute effects of MA but remain
structurally intact. A subsequent study in rats demonstrated
that a neurotoxic dose regimen of MA can produce a
decrease in both DAT and VMAT2 throughout the striatal
complex (Frey et al. 1997), indicating that VMAT2 binding
assays are able to reveal nerve terminal damage induced by
MA. Thus, Frey et al. (1997) concluded that their data and
the results obtained by Wilson et al. (1996) suggest that
long-term high dose MA abuse in humans does not
necessarily produce structural damage to nigrostriatal
nerve endings.
In addition to the evidence in humans for MA induced
neurochemical changes, several studies also reported
functional deficits in cognitive and motor functions.
However, many of these studies were conducted with
active users (Simon et al. 2000, 2002; Ornstein et al. 2000).
To evaluate whether deficits persist, designs employing
testing after a period of abstinence are required. Testing
after a period of drug abstinence also decreases the
likelihood that the observed cognitive impairment is due
to residual drug or withdrawal effects. Kalechstein et al.
(2003) found that the MA users who were abstinent for 5–
14 days still performed significantly worse than controls on
measures of attention/psychomotor speed (Symbol Digit
Modalities Test), learning/memory (Rey Auditory Verbal
Learning Test, Wechsler Memory Scale-III Logical Mem-
ory), and executive function (Controlled Oral Word
Association, Ruff Figural Fluency Test). On the other
hand, there were no differences in the performance
between the MA users and control group on many other
measures of attention/psychomotor speed, visuospatial
skills, learning/memory, or executive functioning.
In a study conducted by Salo et al. (2002), individuals
who were MA-dependent but were abstinent for a period of
2–4 months were compared to normal controls on a
computerized single-trial version of the Stroop Test, which
is thought to assess selective attention. Results indicated
that the MA group had greater rates of interference despite
intact priming, which the authors interpreted as indicating
an impaired ability to suppress irrelevant information.
Clinically, this reduced cognitive inhibition may present as
increased distractibility and difficulty with concentration.
Chang et al. (2002) administered a computerized
cognitive test of reaction time and working memory
[California Computerized Assessment Package (CalCAP)],
as well as measures of psychomotor speed, fine and gross
motor function, and verbal memory and executive function
to 20 MA users who were abstinent for a minimum of
2 weeks (range 2 weeks to 36 months). They reported that
although the MA users exhibited performance deficits
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relative to controls on several CalCAP tasks that involve
reaction time and working memory, the MA users as a
group performed similarly to the controls on many other
measures of cognitive function. Furthermore, the magni-
tude of the observed deficits was not correlated with any
aspect of MA use.
In the study by Volkow et al. (2001b) that demonstrated
decrease in levels of DAT binding after 2 weeks to
36 months of abstinence, the MA users were also evaluated
with a battery of cognitive tests. The magnitude of the
striatal decrease in DAT binding was inversely correlated
with motor speed and memory performance but there was
no correlation with measures of attention (CalCAP, Symbol
Digit Modalities Test, Trail Making Test, and Stroop
Interference Test). In the second study by Volkow et al.
(2001a) demonstrating partial recovery in DAT binding
with longer periods of MA abstinence, there were also
improvement trends in one measure of motor (timed gait)
and memory function (delayed recall), but these were not
statistically significant.
The human studies reviewed above, in combination with
laboratory animal studies, allow the conclusion that high
dose MA abuse leads to neurochemical changes in DA
systems in the brain. It is important to note, however, that it
is not clear whether these changes are due to structural
damage to DA neuron terminals or to regulatory adapta-
tions in an intact population of nerve terminals. The present
study was designed to investigate this issue by using the
PET ligand (+)-α-[11C]dihydrotetrabenazine ([11C]DTBZ)
that binds selectively to the vesicular monoamine trans-
porter (VMAT2), which is a more stable marker of the
integrity of DA nerve terminals than DAT. [11C]DTBZ
binding cannot differentiate DA and 5-HT terminals,
however, over 95% of its striatal binding is attributable to
the dopaminergic nigrostriatal pathway. To compare results
with previous studies, PET scans were also done on each
participant using the DAT ligand, [11C]methylphenidate
([11C]MPH). If decrease in concentrations of both DATand
VMAT2 were found in the nigrostriatal pathway of former
MA abusers in comparison to matched controls, this would
support the hypothesis that there are long-term structural
changes in DA neuron terminals in that brain region.
Furthermore, to evaluate the functional consequences of
any changes, both the MA users and controls were assessed
with a cognitive test battery that incorporated a wide
variety of measures designed to assess motor function,
memory, learning ability, and reasoning.
Materials and methods
Participants
All participants had to be in good health, be between 18
and 55 years of age, have a high school education, and an
estimated IQ of 85 or greater according to the Revised
Shipley Institute of Living Scale (Zachary 1986). Partici-
pants who had experienced head trauma, had a history of a
seizure disorder, met the criteria for bipolar disorder or
schizophrenia, or were taking a proscribed medication
(e.g., antidepressants) were excluded. Female subjects
could not be pregnant or lactating.
MA users were recruited from sites in the San Francisco,
Los Angeles, and Detroit areas through advertisements in
newspapers and word-of-mouth. MA participants met the
above criteria and additionally had to have negative urine
drug tests for stimulants, opiates, benzodiazepines, and
cocaine at screening and before all assessments. All MA
users had to report heavily using MA for at least a 3-month
period with toxic effects, which included agitation,
sleeplessness, paranoia, and tremors and had to meet
Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV criteria for Amphetamine Dependence in the
past, but had to be in at least early partial remission (i.e.,
only one or two of the criteria for dependence were met for
at least 1 month but less than 12 months) with no MA use
for a minimum of 3 months. Previous abuse of or
dependence on other drugs was allowed as long as the
diagnosis was not current (at least 1 year without meeting
DSM-IV criteria). Nicotine dependence was allowed.
Control participants who were recruited from the Detroit
area only had to report not to have used any illegal drug
more than 50 times except marijuana, no history of drug
dependence, and not used any illegal drug except marijua-
na within the past year. They also had to provide a urine
sample that tested negative for stimulants, opiates,
benzodiazepines, and cocaine at screening and before all
assessments. Control participants were matched on a one-
to-one basis to MA users in age, sex, ethnicity, and
estimated IQ scores.
Eligibility was determined during a screening interview
either at the site of origin for those from Los Angeles and
San Francisco or in Detroit. Occasionally, some of the
screening tests could not be performed at the remote site
and were completed in Detroit. Screening evaluations
included obtaining drug use and medical history; a
pregnancy test for females; electrocardiogram, physical,
blood, and urine analysis; urine drug screen; a psychiatric
interview using the Structured Clinical Interview for DSM-
IV (First et al. 1996); and administration of the Shipley
Scale. MA users resided on a locked inpatient research unit
for 3 to 4 days while the procedures were being completed
whereas control participants resided at home and came to
the laboratory on study days.
After complete description of the study to the partici-
pants, written informed consent was obtained. Participants
were paid for their time and inconvenience. The study was
carried out in accordance with the Declaration of Helsinki
and regulations of the United States Department of Health
and Human Services and was approved by the Wayne State
University Institutional Review Board.
Procedures
Eligible participants were assessed with two procedures.
These included determination of striatal VMAT2 and DAT
binding site densities using [11C]DTBZ and [11C]MPH,
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respectively, and PET and a battery of neurocognitive tests.
The scheduling of these two evaluations was determined by
the availability of PET scanner time. For all MA users,
evaluations were conducted within a 3-day period. This
was also true for most control participants but for some, the
interval was longer but never more than 30 days. Smoking
was allowed up to the time that sessions began and for the
neuropsychological testing, there was a break during which
smokers could smoke.
Positron emission tomography of neurotransmitter
transporter binding
The distribution and density of VMAT2 binding sites was
determined with the use of PET and the radioligand [11C]
DTBZ as described previously (Koeppe et al. 1997).
Subjects were positioned supine in the PET scanner
(Seimens/CTI Exact HR+ tomograph) gantry with eyes
and ears unoccluded. A transmission scan was obtained for
attenuation correction immediately before radiotracer
administration. In determinations of VMAT2 binding, a
bolus injection was given followed by a 59-minute
continuous intravenous infusion of [11C]DTBZ (containing
10–18 mCi and less than 50 μg mass). Prior studies have
demonstrated that administration of 55% of the total
dosage as a bolus over 1 min followed by the remaining
45% administered as a continuous infusion over 59 min
produces constant arterial and brain tracer levels after
30 min (Koeppe et al. 1997). After a 60-min period to allow
the further decay and elimination of [11C]DTBZ activity,
determinations of DAT binding site density were made
with the use of MPH. An imaging protocol similar to that of
the DTBZ study was used, employing approximately
18 mCi of [11C]MPH administered as a loading bolus (60%
of the dose) over the first minute followed by a constant
infusion of the remaining 40% of the dose over the next
79 min.
In [11C]DTBZ binding scans, dynamic brain imaging
was obtained over 60 min. Early image frames (0 to 4 min
postinjection of the [11C]DTBZ bolus) were used to
estimate the blood-brain barrier (BBB) transport rate and
were employed in voxel-based analyses requiring gray
matter structural delineations. Three frames acquired for
10 min each between 30 and 60 min postinjection were
used to estimate VMAT2 binding site density (Koeppe et
al. 1997). In [11C]MPH scans, early image frames (0 to
4 min postinjection) were again used for BBB transport and
anatomic registration, while two 10-min frames from 60 to
80 min post injection were used to estimate [11C]MPH
binding (Volkow et al. 1995; Sossi et al. 2000).
Images were reconstructed by filtered backprojection
with a Hanning 0.5 filter using the measured tissue
attenuation coefficients and calculated scatter correction.
Summed reconstructed images from 30 to 60 min for [11C]
DTBZ or 60 to 80 min for MPH, which depicted the total
tissue equilibrium tracer distribution volumes (DVTOT),
were employed to calculate striatal VMAT2 or DAT
binding site densities. Volumes-of-interest (VOI) were
extracted from the striatum in each subject’s parametric DV
maps, delineating the maximal activity in each of three
rostrocaudal regions (dimensions 2.25 mm cra-
niocaudal×9 mm anteroposterior×4.5 mm mediolateral)
representing the caudate nucleus, the anterior putamen, and
the posterior putamen in each hemisphere. We estimated
the nonsaturable components of [11C]DTBZ or [11C]MPH
DVTOT (DVREF representing nonspecific binding and free
ligand contributions) from the occipital cortex (Brodmann
areas 17, 18, and 19) as a reference region known to be free
of detectable VMAT2 binding sites in [11C]DTBZ PET
(Koeppe et al. 1999) and of very low DAT expression
(Volkow et al. 1995; Sossi et al. 2000). Our measure of
specific [11C]DTBZ or [11C]MPH bindings, the binding
potential (BP) was calculated as follows:




The neurocognitive test battery included tests of general
cognitive ability for IQ estimates, motor performance,
explicit memory that assesses both encoding and retrieval
components, working memory, and executive function.
The battery also included tests from the Cambridge
Automated Neuropsychological Assessment Battery
(CANTAB) that are performed by the participant on a
computer terminal using a touch screen or button press
(Robbins et al. 1994, 1998).
Estimated IQ was based on scale scores obtained on the
Vocabulary and Block Design subtests of the Wechsler
Adult Intelligence Scale (WAIS)-III (Wechsler 1997). The
Vocabulary/Block Design dyad was shown to yield
estimated IQs that correlated highly with the WAIS-III
Full Scale IQ using data both from the WAIS-III standard-
ization sample (r=0.88; Sattler and Ryan 2001) and from a
clinical sample (r=0.91; Ringe et al. 2002). Motor
performance was measured using the finger-tapping task
(Reitan 1969), grooved pegboard (Klove 1964), and the
Digit Symbol Substitution test (DSST) (Wechsler 1997).
The California Verbal Learning Test (CVLT) and the
Paired Associates Learning (PAL) Task (CANTAB) were
used to measure explicit memory. The CVLT (Delis et al.
1987) involves learning a “shopping” list of 16 items over
five trials. After five trials, an interference list of 16 words
is presented for one trial immediately followed by free
recall and category-cued recall of the first list. After a 20-
min delay during which nonverbal testing is conducted,
free recall, cued recall, and recognition of the first list are
tested. The PAL is a form of a visuospatial memory
procedure of explicit memory. The computer screen
contains 6 to 8 boxes and one by one in a random
sequence these are “opened,” revealing the location of a
pattern. The participant is asked to remember the location.
The number of patterns is increased to two, then three, then
six and finally eight. Advancement to a new set cannot
occur until the previous set is completed correctly. Total
and average errors prior to successful completion, number
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of sets successfully completed on the first try, and number
of sets completed correctly are measured.
Working memory was evaluated using three tasks from
the CANTAB. In the Spatial Working Memory (SWM)
task, a trial begins with a number of colored squares
(boxes) shown on a computer screen. The goal is to find a
blue “counter” in one of the boxes and “transfer” it to fill up
an empty column on the right hand side of the screen. The
participant must touch each box in turn until one opens
with a blue counter inside (a search). The number of boxes
appearing on the screen increases from three (practice) to
four, to six, and to eight. Returning to an empty box already
sampled (within error) or returning to a box where a
counter was already found (between error) constitutes an
error. In the Delayed Match to Sample (DMS) task,
participants are asked to choose the correct stimulus out of
four that was presented 0, 4, or 12 s previously. Percent
correct under each condition is measured. Finally, the
Rapid Visual Information Processing (RVIP) is a test of
sustained attention with a small working memory compo-
nent. A white box appears in the center of the computer
screen, inside which digits from numbers 2 to 9 appear in a
pseudorandom order at the rate of 100 digits/min.
Participants are asked to monitor the changing digits for
predefined number sequences and to press a button upon
presentation of the final digit of a sequence. Total hits
(correct button press), total false alarms (incorrect button
press), and total misses (failure to press button after target
sequences) are measured.
Executive function was measured using the standard
Trail Making Test (parts A and B; Reitan 1958) and two
word list generation tasks. In the first word list generation
task, the participant is asked to name as many words as
possible that begin with a designated letter (F, A, or S)
within 60 s. The score is the total number of words
(excluding duplicates and changes of suffix) named across
letters. The second word list generation task is similar
except the participant is asked to name as many animals as
possible within 60 s.
Two additional measures of executive function were
tasks from the CANTAB. The intradimensional/extradi-
mensional (ID/ED) shift task is a computer version of the
Wisconsin Card Sorting Task. This test measures ability to
attend to the specific attributes of compound stimuli and to
shift that attention when required. The first seven stages
(early stages) only require intradimensional shifts whereas
at stage 8, an extradimensional shift is required and stage 9
requires a reversal. Stages completed, errors when the shift
required is intradimensional (ID shift errors), and errors
when the shift required is extradimensional (ED shift
errors) are measured. In addition, the percentage of
individuals who reached the criterion at each of the nine
stages in each group was also calculated. The Stockings of
Cambridge test requires spatial planning and is based upon
the Tower of London. The participant is shown two
displays containing three colored balls. The participant
must move the balls in the lower display to copy the pattern
shown in the upper one. Participants are encouraged to plan
their moves carefully. The minimum number of moves
required increases from 2 to 5 and mean initial thinking
time (i.e., time until first move), subsequent thinking time
(i.e., time from first move to completion), and number of
moves for each display are measured.
Data analyses
The BP of [11C]DTBZ and [11C]MPH in the striatal VOI
were compared across the MA and control groups using
unpaired t tests. In addition, Pearson product–moment
coefficient correlations among striatal [11C]DTBZ and
[11C]MPH BPs and between these levels and drug use were
computed.
Except for comparing the percentage of individuals in
each group who completed the criterion for each stage of
the ID/ED shift test, the neurocognitive data were analyzed
using two-factor univariate ANOVAs with each group
(user or control) as the between-subject factor. The percent
completion of ID/ED shift stages was analyzed by a chi-
square. In addition, correlations between performance
measures and drug use measures were computed.
Two sets of exploratory correlational analyses were done
in MA users. The BP of [11C]DTBZ and [11C]MPH in the
caudate, putamen, and striatum and the motor function
measures (Finger Tapping and Grooved Peg Board) were
correlated as previous studies showed significant correla-
tions in former MA users (Volkow et al. 2001a). The
second set were correlational analyses between the BP of
both ligands in these same areas and any neurocognitive




There were 16 MA users and 18 controls for a total of 34
participants. The neuroimaging data for one of the MA
users (white woman, 38) and one of the controls (white
man, 25) could not be obtained because of radiotracer
synthesis problems. Data from another control participant
(white man, 38) was not used in the analyses because of
movement artifact. Thus, for the neuroimaging results, the
total number of participants was 31 (15 MA users and 16
controls) whereas there were 34 participants tested on the
neurocognitive measures. Age, IQ, and gender/race distri-
bution are shown in Table 1. Most participants were white
and there were more men than women. There were no
significant differences in these demographics across
groups.
Although bipolar disorder and schizophrenia were
exclusionary, other Axis 1 disorders were not. Whereas
nine of the MA users had no other DSM-IV diagnoses, six
met the criteria for Major Depressive disorder (MDD) with
five in full and one in partial remission. Two MA users met
the criteria for a specific phobia, two for social phobia, and
one for panic disorder. Except for the individual who met
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the criteria for panic disorder, those with these other
diagnoses also had MDD.
All MA users met the DSM-IV criteria for Amphetamine
Dependence. The average years of regular use (defined as
three or more times per week) of MA was 10.3 years, but
this ranged from 1 to 30 years with a median of 10 years.
Participants used MA either by snorting or smoking (or
both) with only one individual reporting using it intrave-
nously. Average years since last regular use was 3.4 with a
range of 3 months to 18 years and a median of 1 year. To be
eligible, participants had to have a drug-free urine for
opiates, benzodiazepines, or cocaine at the time of
screening and testing. While they could have used
recreational drugs recently, this, to a large extent was not
the case as seen in Table 2. Except for one person who used
cocaine, one who used marijuana, and four who drank
alcohol within the last 30 days, participants had almost
totally abstained from any drug use for at least that time and
in many cases longer (Table 2). However, all MA users had
a history of abuse and dependence on other drugs as seen in
Table 3. None of these diagnoses were current except
nicotine dependence. Control participants had used mini-
mal recreational drugs as shown in Table 3 and were
required to report no use of illegal drugs except marijuana
for a year. Most were current users of alcohol but none met
the criteria for any current drug abuse or dependence.
Eleven of the MA users and two of the controls were
current smokers.
To qualify for the study, MA participants had to report at
least one 3-month period when they experienced MA-
induced toxic symptoms (agitation, sleeplessness, para-
noia, or tremors). Table 4 shows the number of participants
who met this three-month criterion for each symptom and
the mean and median number of months the symptom was
experienced. Participants were also asked whether they had
experienced 16 other types of consequences but they were
not asked to indicate for how long. These are listed in
Table 5 with incidence noted.
Neuroimaging results
There were statistically significant differences in VMAT2
binding in the caudate nucleus, anterior putamen, and
striatum with the MA group having about 10–11% lower
levels (Table 6 and Fig. 1). In addition, DAT binding was
also significantly lower (12–16%) for the MA group in all
regions of the striatum (Fig. 2). While the decreases were
greater for DAT, the differences compared to VMAT2 were
not statistically significant.
VMAT2 concentrations were highly correlated across all
striatal brain regions. There were no consistent correlations
in either MA use parameter (i.e., duration of regular use
and time since last regular use) and the levels of availability
of DAT or VMAT2.
Neurocognitive effects
Analyses of results failed to reveal statistically significant
group differences on the following tasks: Finger Tapping,
Grooved Pegboard, PAL, Trail Making A and B, Phonemic
Verbal Fluency (FAS) and Animal Fluency, Intra/Extra-
dimensional Shift, Stockings of Cambridge, SWM, and
DMS (Table 7).
As also shown in Table 7, MA users performed
significantly more poorly than controls on the DSST and
all measures of the CVLT. On the RVIP, MA users
performed less well on number of hits, misses, correct
rejections, and probability of a hit. None of these
significant differences were correlated with years of regular
use or years since regular use with one exception. There
was a significant correlation between CVLT trial 5 raw
scores and years since regular use but this correlation was
negative indicating that the longer the abstinence, the lower
the scores (r=−0.051, p<0.042). A scatter plot of the data
Table 1 Participant characteristics
MA (n=16) Controls (n=18)
Age 32 (21–48) 31 (18–48)
IQ* 101.81 105.61
Ethnicity/Gender
White/Male 9 (56%) 10 (56%)
Black/Male 2 (13%) 2 (11%)
White/Female 5 (31%) 6 (33%)
*Based on summed scale scores on WAIS-III vocabulary and block
design subtests
Table 2 Number of MA participants who reported they did not use
any of the listed recreational drugs even once at various time periods
Had not used in less than 1 month 3 months 6 months 1 year
Methamphetamine 16/16 16/16 8/16 8/16
Other stimulants 10/10 9/10 9/10 7/10
Cocaine 14/15 14/15 13/15 11/15
Marijuana 15/16 12/16 11/16 7/16
Alcohol 11/14 7/14 6/14 5/14
Opioids 10/10 9/10 9/10 6/10
Sedatives 9/9 9/9 9/9 8/9
The denominator indicates the number of individuals who ever had
used the drug lifetime
Table 3 Other lifetime drug use (controls) or abuse/dependence
(MA users)
MA Controls
Drug Abuse (%) Dependence (%) Use (%) any/current
Stimulants 100 11/0
Alcohol 31 31 100/78
Cocaine 0 31 11/0
Marijuana 0 38 78/0
Opioids 0 19 0/0
Sedatives 0 19 0/0
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revealed an outlier, someone who had not used drugs in
14 years but did very poorly on all measures of the CVLT.
When this participant’s data were removed from the




There were no significant correlations between [11C]DTBZ
or [11C]MPH bindings and any of the measures of motor
function. There were significant positive correlations
between the BP of [11C]DTBZ in caudate nucleus
(r=0.53, p<044), putamen (r=0.57, p<0.026), and striatum
(r=0.57, p<0.026) with only CVLT short delay recall,
indicating that lower BP was associated with impaired
performance. For [11C]MPH binding levels, there were no
significant correlations.
Discussion
There is ongoing controversy concerning the potential
neurotoxicity of MA at the dosages and exposure
frequencies employed by human psychostimulant abusers.
While experimental animal models of MA effects permit
detailed, mechanistic approaches to the study of its
pharmacological and toxic effects, interspecies differences
and other aspects of drug dosage and exposure patterns
may confer important distinctions in the case of human
psychostimulant users. To directly explore the issue of
human MA toxicity, we conducted PET measurement
imaging of DAT and VMAT2 together with neurocognitive
assessments in abstinent MA users. The current study is the
first to use VMAT2 PET to investigate in vivo the integrity
of DA nerve terminals in the striatum of abstinent MA
abusers. In the present study, statistically significant lower
levels of both VMAT2 and DAT binding sites were found
in the former MA users, indicating the possibility of nerve
terminal degeneration.
Our present finding of decrease in availability of striatal
DAT binding sites in former MA abusers is consistent with
previous PET studies of abstinent MA abusers (McCann et
al. 1998; Volkow et al. 2001b). It is of interest to note that
the magnitude of the decrease in availability of DAT in the
present study was smaller than in the previous two studies.
The reason for this discrepancy is not apparent. However,
the failure to find correlations between BP and duration of
use and abstinence rules out these potential differences
from other studies.
Despite the relatively small magnitude of the lower
levels of availability, the fact that both DAT and VMAT2
were decreased in former MA abusers strongly supports the
hypothesis that there are long-term structural changes in the
DA nerve terminals in these regions. It was argued that
reductions in DAT levels may reflect changes in its
expression or subcellular trafficking rather than indicating
structural damage to DA nerve terminals (Harvey et al.
2000). In the present study, the finding that both VMAT2
and DAT binding levels were significantly decreased in
individuals who have not used MA for as long as 30 years
and that BP was not correlated with years of abstinence are
strongly suggestive of irreversible structural changes, at
least in a fraction of striatal DA nerve terminals. As
opposed to possible regulatory and subcellular localization
influences on DAT binding, VMAT2 binding is relatively
unaltered by nontoxic pharmacological interventions that
alter DA signaling and tracks closely with lesion intensity
in preclinical neurotoxin lesion studies (Vander Borght et
al. 1995a,b). While the present results therefore support a
long-lasting depletion of nigrostriatal DA terminals in
former MA users, the magnitude of the reduction (10–15%)
is unlikely to lead directly to clinical symptoms of DA
deficiency. Parallel studies of [11C]DTBZ PET imaging in
hemi-Parkinson disease (PD) patients (Bohnen et al. 1996)
indicate that more than 75% of VMAT2 sites in the
posterior putamen are lost before clinical signs and
symptoms develop.
Because of the role of the striatal DA system in motor
function, investigators were concerned that MA-induced
toxicity in this area might predispose previous users to
develop symptoms of PD. However, studies in rhesus
monkeys failed to show any deficits in motor function as
Table 4 Consequences of MA use
Met 3 month
criterion (n=15)*
Duration of recurring symptom in
months (mean, median)
Agitation 11 69, 48







*Data not available for one of the 16 participants.
Table 5 Other self-reported symptoms






Unable to stop 14
Lack of appetite 15
Accident/injury 6




Fight or quarrel 13




measured by hand-steadiness (Johanson et al. 1979) or
visual pursuit tracking (Ando et al. 1986) after a high dose
regimen of MA that produced large decreases in DA
neuronal markers but with an intervening period of
abstinence. In contrast, studies in short-term abstinent
MA abusers reported that the magnitude of the striatal
decrease in DAT binding was inversely correlated with
motor speed both in the Timed Gait and the Grooved
Pegboard tasks (Volkow et al. 2001b). However, a
subsequent study by Chang et al. (2002) did not show
any deficits in MA users abstinent for on average of
8 months in either Timed Gait or Grooved Pegboard in
comparison to normative values. The present investigation
also failed to show any motor deficits in rate of Finger
Tapping or speed in completing the Grooved Pegboard.
Thus, it does not appear that there are motor function
deficits suggestive of early PD in either recent or long-term
abstinent MA abusers. It remains possible that previous
MA exposure may increase the risk of PD later in life, but
the magnitude of this contribution is likely to be minor in
comparison to yet undetermined genetic or other environ-
mental factors.
Of equal concern is whether neurotoxic changes in the
caudate nucleus may result in long-term, possibly irrevers-
ible deficits in cognitive function as suggested by
Moszczynska et al. (2004). In the present study, MA
users showed deficits in the DSST of the WAIS-III relative
to the controls. However, neither the mean standard score
(9.63) nor individual scores were greater than one SD (3)
below the age-controlled norm (10.0). This finding
suggests that although MA may produce long-term,
possibly irreversible deficits in speed and accuracy of
information manipulation, these deficits are relatively
small and for some may not reach clinical significance.
Using a task of attentional set-shifting ID/ED from the
CANTAB, Ornstein et al. (2000) found that a larger
percentage of current amphetamine abusers were less likely
to learn discrimination when an extradimensional shift was
required compared to controls. In the present investigation
using the same test battery, no differences between MA
users and matched controls were found. The failure to
replicate the results by Ornstein et al. (2000) may be due to
the length of abstinence from MA and perhaps, lack of
comorbidity or other recent drug use.
A few investigators reported that MA abusers show
memory deficits even after periods of abstinence (e.g.,
Kalechstein et al. 2003). In the present investigation, MA
users showed significantly poorer performance on several
of the subtests of the CVLT including both cued and
noncued short and long delayed recall. However, despite
this statistically significant difference compared to con-
trols, their performance was not outside the normal range
Fig. 2 Scatter plot of [11C]MPH binding potential in the caudate
nucleus and anterior and posterior putamen. The open circles
represent individuals in the control group (n=16) and triangles
represent individuals in the methamphetamine group (n=15)
Table 6 Striatal VMAT2
and DAT binding potentials
*p<0.05
**p<0.01
Caudate nucleus Anterior putamen Posterior putamen Putamen Striatum
[11C]DTBZ
MA (n=15) 2.20 (0.25)* 2.60 (0.26)* 2.66 (0.28) 2.63 (0.26) 2.48 (0.25)*
Controls (n=16) 2.48 (0.40) 2.91 (0.42) 2.95 (0.51) 2.93 (0.46) 2.78 (0.42)
MA/Controls % 89 89 90 90 89
[11C]MP
MA (n=15) 1.56 (0.15)** 1.81 (0.15)* 1.77 (0.19)* 1.79 (0.16)* 1.72 (0.15)**
Controls (n=16) 1.85 (0.30) 2.04 (0.32) 2.01 (0.35) 2.03 (0.33) 1.97 (0.32)
MA/Controls % 84 89 88 88 87
Fig. 1 Scatter plot of [11C]DTBZ binding potential in the caudate
nucleus and anterior and posterior putamen. The open circles
represent individuals in the control group (n=16) and triangles
represent individuals in the methamphetamine group (n=15)
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Table 7 Neurocognitive test results [mean (SE)]
Controls (n=18) MA (n=16)
Psychomotor function
Finger Tapping
Dominant hand 53.19 (9.03) 48.63 (5.40)
Non-dominant hand 48.77 (7.07) 46.04 (8.13)
Grooved Pegboard
Dominant hand 66.44 (9.73) 67.06 (9.84)
Non-dominant hand 70.72 (16.44) 76.25 (10.80)
WAIS-III digit symbol (standard score) 11.17 (1.42) 9.63 (2.16)*
Explicit memory
CVLT
Trial 1 8.39 (2.12) 6.94 (1.81)*
Trial 5 13.44 (1.82) 11.75 (1.53)*
Short delay free recall 12.61 (2.28) 9.94 (2.35)*
Short delay cued recall 12.94 (2.24) 11.25 (2.18)*
Long delay free recall 12.44 (2.38) 10.38 (2.58)*
Long delay cued recall 13.00 (2.03) 11.13 (1.93)*
PAL
Total errors 8.22 (10.84) 12.00 (11.96)
Mean errors to success 1.03 (1.36) 1.50 (1.50)
Stages completed 1st trial 6.44 (0.92) 5.88 (1.20)
Stages completed 8.00 (0.00) 8.00 (0.00)
Executive function
Trails
Trail A time (s) 28.00 (8.94) 30.81 (12.68)
Trail B time (s) 65.94 (37.18) 63.25 (18.31)
Word List
FAS (number) 39.39 (12.65) 40.75 (9.18)
Animal Fluency (number) 22.06 (6.31) 21.69 (5.59)
Intra/Extradimensional Shift (CANTAB)
Stages completed 8.44 (0.86) 8.13 (1.02)
Pre-extradimensional shift errors 5.50 (1.89) 8.06 (5.98)
Extradimensional shift errors 11.72 (11.16) 13.50 (12.07)
Total errors 22.26 22.63
Completed stage errors 13.22 11.25
Stockings of Cambridge (CANTAB)
Moves (2 move solutions) 2.00 (0.00) 2.00 (0.00)
Moves (3 move solutions) 3.28 (0.49) 3.03 (0.13)
Moves (4 move solutions) 4.96 (1.17) 5.11 (1.30)
Moves (5 move solutions) 6.68 (1.48) 6.77 (1.31)
Initial time (s; 2 moves) 2.81 (2.05) 2.45 (0.89)
Initial time (s; 3 moves) 7.46 (3.32) 7.00 (4.05)
Initial time (s; 4 moves) 8.46 (3.57 9.03 (6.49)
Initial time (s; 5 moves) 9.89 (4.49) 10.52 (6.15)
Subsequent time (s; 2 moves) 0.42 (0.85) 0.34 (1.16)
Subsequent time (s; 3 moves) 0.54 (0.82) 0.11 (0.22)
Subsequent time (s; 4 moves) 0.94 (0.97) 0.99 (1.09)
Subsequent Time (s; 5 moves) 1.05 (0.97) 0.95 (0.91)
Working memory
Spatial Working Memory (CANTAB)
Between errors (4 boxes) 0.94 (2.10) 1.13 (2.09)
Within errors (4 boxes) 0.61 (1.91) 0.13 (0.50)
Between errors (6 boxes) 7.22 (8.08) 6.56 (7.15)
Within errors (6 boxes) 0.78 (1.63) 0.81 (1.87)
Between errors (8 boxes) 18.28 (12.60) 16.69 (10.53)
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for their age group. Thus, the functional significance of
these differences in memory function is questionable.
Nevertheless, it seems likely that these deficits are
permanent because they were not correlated with duration
of abstinence. It is obvious that the possibility remains that
these deficits predated drug use but the present study
cannot address this possibility.
On the RVIP of the CANTAB, which is thought to assess
attentional function and distractibility, MA abusers showed
significantly poorer performance in all measures. Several
investigators found out that MA abusers show increased
interference on the Stroop Color Word Interference Test.
For instance, Simon et al. (2000) found that individuals
who had used MA for an average of 11 years and were
currently using were significantly impaired in their ability
to ignore irrelevant information (Stroop Color-Word Inter-
ference Test). Salo et al. (2002) using a single trial version
of the Stroop Test also showed greater rates of interference
in individuals who were abstinent from MA for 2–
4 months. This attentional deficit seen in the MA abusers
and our findings on the RVIP may be related to the
distractibility described by clinicians treating MA abusers.
Although MA users showed poorer performance on
several tests on the neurocognitive test battery, in most
cases their performance was no different than controls.
There were no differences in measures of motor function
(Finger Tapping and Grooved Pegboard), one of the two
measures of explicit memory (PAL), executive function
(Trails A and B, FAS and Animal Fluency, Intra/
Extradimensional Shift, and Stockings of Cambridge), or
working memory (SWM and Delayed Matching to Sam-
ple). While previous studies showed a greater degree of
cognitive impairment even in those studies, many functions
remained intact.
There are a number of caveats for this and other studies
attempting to determine the long-term neurochemical and
functional consequences of high doseMA abuse in humans.
First, with very few exceptions, MA abusers in these studies
were polydrug abusers. Where differences in brain chem-
istry and motor or cognitive functions are found, it is
necessary to use a control group that is matched in other
drug use. This was not done in any of the studies to date and
would be an extremely difficult undertaking because
investigators would also have to control for amount of use
and length of abstinence. However, in the present study,
participants did not report extensive drug use in the last
3 months and for many, they did not use drugs for years. A
second caveat is that comorbid disorders could have
affected the results. However, few comorbid disorders
were diagnosed and of those participants with MDD, all but
one of the six were in full remission. Unfortunately in this
study, and most of those finding cognitive deficits in former
MA abusers, no attempt was made to determine whether the
participants met the criteria for Attention Deficit Hyperac-
tivity disorder (ADHD). This is important because the
prevalence of ADHD is high in substance-abusing popula-
tions (Biederman et al. 1995). Future studies should make
every attempt to control for the presence of ADHD in
studies comparing the cognitive status of controls and MA
abusing research participants.
In conclusion, decreases were noted in the BPs of DAT
and VMAT2 and several measures of cognitive function in
former MA users compared to controls. Fortunately, the
magnitude of the differences was small and may not have
major functional significance. This finding, if confirmed by
others, should lead to a more optimistic attitude on the part
of treatment practitioners and those in recovery from MA
abuse/dependence.
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Controls (n=18) MA (n=16)
Within errors (8 boxes) 1.78 (2.51) 0.81 (1.56)
Delayed Matching to Sample (CANTAB)
Percent correct (short delay) 88.33 (12.95) 88.75 (8.85)
Percent correct (medium delay) 92.22 (11.66) 90.00 (7.30)
Percent correct (long delay) 83.89 (15.39) 82.50 (12.91)
Rapid Visual Information Processing (CANTAB)
Total hits 18.06 (4.71) 14.50 (3.29)*
Total misses 8.94 (4.71) 12.50 (3.29)*
Total correct rejections 251.11 (10.81) 243.44 (8.03)*
Probability of hit 0.67 (0.17) 0.54 (0.12)*
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